Xiidra has ~90% OVERALL COVERAGE for Medicare Part D and Commercial patients nationwide*[1]

xiidra® (lifitegrast ophthalmic solution)5%

- For most major COMMERCIAL PLANS, Xiidra coverage exceeds Restasis®[1]
- For most major MEDICARE PART D PLANS, Xiidra offers equal coverage to Restasis[2]

Help your appropriate patients gain access to Xiidra with this helpful checklist for prior authorizations (PAs)

Use this checklist to help ensure necessary information is documented

Note: Not all of these requirements may apply, and there may be other requirements not included in this list.

☐ MEDICATION

Medication name (eg, Xiidra)	Quantity (eg, 180 each per 90 days, 60 each per 30 days)

☐ PATIENT'S CLINICAL RECORDS (including medical history)

Patient-reported dry eye symptoms, for example[3]:

- Dryness
- Watery eyes
- Itchiness
- Stinging
- Burning
- Irritation
- Grittiness
- Redness
- Blurry vision
- Feeling like something is in the eye

Clinical observations, for example[3]:

- Systemic inflammatory conditions
- Decreased tear production
- Severity of disease

Clinical diagnosis of dry eye disease (DED), including the following information:

- Date of diagnosis
- Valid ICD-10 diagnosis code with the full set of 3 to 7 characters and description ⚠
- Diagnostic testing and results, which may include at least 1 of the following[3]: ⚠
  - External eye examination
  - Tear film breakup time (TBUT)
  - Aqueous tear production (Schirmer's test)
  - Corneal and conjunctival staining
  - Blink rate
  - Validated questionaire
  - Matrix metalloproteinase-9 (MMP-9) test
  - Tear osmolarity
  - Corneal sensitivity
  - Slit-lamp exam

Prior treatment history for DED

- Drugs tried and failed, if any (failure may require inadequate response to at least 1 formulary alternative or over-the-counter medication [eg, artificial tears, lubricants, gels, or ointments]), including the following information: ⚠
  - Product name
  - Dose
  - Frequency of use
  - Dates of treatment
  - Response to treatment
  - Outcome

Functional impact of DED, if any, such as the ability to perform the following daily tasks[3]:

- Reading
- Using a computer
- Driving at night
- Productivity at work

Attach a copy of your patient's medical records, including chart notes, when required by the plan

☐ ENSURE YOUR SIGNATURE IS INCLUDED (when required by the plan)

☐ ENSURE YOUR PATIENT'S INFORMATION (including **prescription** insurance) IS CORRECT AND COMPLETE

⚠ **AVOID COMMON ERRORS:** incomplete or missing information in any of these designated categories may result in a PA denial

INDICATION

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

IMPORTANT SAFETY INFORMATION

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.

*Based on data from December 2023. Up to 66% of Medicare Part D and 94% of commercial patients may be covered.

Please see additional Important Safety Information on reverse side. For additional safety information, please see accompanying Full Prescribing Information.

BAUSCH + LOMB

These diagnosis code examples are provided for general informational purposes only and are not intended to be directive, a guarantee of coverage, or a substitute for an independent clinical decision.

xiidra® (lifitegrast ophthalmic solution)5%

EXAMPLE ICD-10 CODES FOR DRY EYE DIAGNOSIS[4]

DESCRIPTION	RIGHT	LEFT	BILATERAL	UNSPECIFIED
Dry eye syndrome of lacrimal gland	H04.121	H04.122	H04.123	H04.129
Unspecified epiphora	H04.201	H04.202	H04.203	H04.209
Keratoconjunctivitis sicca, not specified as Sjögren's syndrome	H16.221	H16.222	H16.223	H16.229
Punctate keratitis	H16.141	H16.142	H16.143	H16.149
Unspecified keratoconjunctivitis	H16.201	H16.202	H16.203	H16.209
Unspecified superficial keratitis	H16.101	H16.102	H16.103	H16.109
Other keratoconjunctivitis	H16.291	H16.292	H16.293	H16.299
Sicca syndrome (Sjögren) with keratoconjunctivitis—M35.01				
Sicca syndrome (Sjögren), unspecified—M35.00				

EXAMPLE ICD-10 CODES FOR DRY EYE SYMPTOMS[4]

DESCRIPTION	RIGHT	LEFT	BILATERAL	UNSPECIFIED
Visual discomfort	H53.141	H53.142	H53.143	H53.149
Other visual disturbances—H53.8				

The information herein is provided for educational purposes only. Bausch + Lomb cannot guarantee insurance coverage or reimbursement. Coverage and reimbursement may vary significantly by payer, plan, patient, and setting of care. It is the sole responsibility of the health care provider to select the proper codes and ensure the accuracy of all statements used in seeking coverage and reimbursement for an individual patient.

Please Note: Bausch + Lomb is unable to complete a PA form or coverage determination form, guide you about what to write on these forms, provide PA criteria if it is not publicly available, or talk to you about a patient's personal health information. It is important to review the insurer's guidelines for obtaining a PA, as these can differ depending on the insurer, the medication being prescribed, and other factors. Guidance included in this document is not inclusive and does not guarantee patient coverage for a product.

PRESCRIBE XIIDRA WITH CONFIDENCE

INDICATION

Xiidra® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of signs and symptoms of dry eye disease (DED).

IMPORTANT SAFETY INFORMATION

Xiidra is contraindicated in patients with known hypersensitivity to lifitegrast or to any of the other ingredients.

In clinical trials, the most common adverse reactions reported in 5-25% of patients were instillation site irritation, dysgeusia and reduced visual acuity. Other adverse reactions reported in 1% to 5% of the patients were blurred vision, conjunctival hyperemia, eye irritation, headache, increased lacrimation, eye discharge, eye discomfort, eye pruritus and sinusitis.

To avoid the potential for eye injury or contamination of the solution, patients should not touch the tip of the single-use container to their eye or to any surface.

Contact lenses should be removed prior to the administration of Xiidra and may be reinserted 15 minutes following administration.

Safety and efficacy in pediatric patients below the age of 17 years have not been established.

For additional safety information, please see accompanying Full Prescribing Information.

NOS, not otherwise specified.

References: 1. Data on file. MMIT Portal, December 2023. Bausch & Lomb, Inc. **2.** Data on file. DRF Fingertip Formulary Datafeed, March 10, 2020. Novartis Pharmaceuticals Corp; March 2020. **3.** Akpek EK, Amescua G, Farid M, et al; American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel. Dry eye syndrome preferred practice pattern. *Ophthalmology*. 2019;126(1):P286–P334. doi:10.1016/j.ophtha.2018.10.023 **4.** Centers for Disease Control and Prevention. ICD-10-CM tabular list of diseases and injuries. Published April 2022. Accessed January 25, 2024. https://ftp.cdc.gov/pub/health_statistics/nchs/publications/ICD10CM/2022/icd10cm-tabular-2022-April-1.pdf

BAUSCH + LOMB